---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-389836"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-09-14T11:15:30+00:00"
generated_at: "2026-09-14T11:20:27.438507+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio names José Trevejo CMO and Ellie Hershberger CDO; bempikibart registration program targeted H1 2027

## Summary
- José Trevejo, M.D., Ph.D. named CMO; ex-CMO at Tarsus (helped win FDA approval of XDEMVY for Demodex blepharitis) and ex-CDO at Rocket Pharmaceuticals.
- Ellie Hershberger, Pharm.D. named CDO; ex-CDO at Adagio/Invivyd, led antibody from IND-enabling to Phase 3 and helped raise ~$356M in IPO gross proceeds.
- Company targets advancing bempikibart into registration-directed program for severe or very severe alopecia areata in first half of 2027.
- Q32 Bio says SIGNAL-AA Part B showed meaningful hair regrowth, early durability off-drug, and generally well-tolerated safety profile for bempikibart.

## SEC filing metadata
- accession: 0001193125-26-389836
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-09-14T11:15:30+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/0001193125-26-389836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/d158730d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-389836
- JSON: https://secwatch.observer/filing/0001193125-26-389836.json
- Plain text: https://secwatch.observer/filing/0001193125-26-389836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.